Seattle, Oct. 11, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global non-small cell lung cancer treatment market is estimated to be valued at US$ 24,910.7 million in 2022 and is expected to exhibit a CAGR of 9.4% during the forecast period (2022-2030).
Key Trends and Analysis of the Global Non-small Cell Lung Cancer Treatment Market:
The increasing number of new drug approvals by regulatory authorities for the treatment of non-small cell lung cancer are expected to drive growth of market. For instance in May, 2019, Pfizer Inc., which is a U.S.-based multinational pharmaceutical and biotechnology corporation received the European Commission’s (EC) marketing authorization for the LORVIQUA drug, a monotherapy drug used for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/241
Key Market Takeaways:
Global non-small cell lung cancer treatment market is expected to exhibit a CAGR of 9.4% during the forecast period due to increasing initiatives to help patients with lung cancer by key players and government. For instance, in January 2021, The Lung Ambition Alliance, which is a global coalition with the bold ambition to eliminate lung cancer as a cause of death, started The Initiatives in Lung Cancer Care (ILC2) program. The aim of the program is to fund projects that drive measurable improvements across the patient journey, from early detection to palliative care or survivorship.
Among end user, hospital segment is expected to hold a dominant position over the forecast period, owing to increasing prevalence of the non-small cell lung cancer. For instance, according to data published in May 2022, by Canadian Cancer Society, which is Canada's national cancer charity and the national charitable funder of cancer research in Canada, estimated that 30,000 Canadians will be diagnosed with lung and bronchus cancer in 2022.
On the basis of region, North America segment is expected to hold a dominant position over the forecast period, owing to increasing number of drug approvals by the U.S. Food and Drug Administration for the treatment of non-small cell lung cancer. For instance, in April 2018, AstraZeneca Pharmaceuticals LP, which is a global, science-led biopharmaceutical comapny, received the U.S. Food and Drug Administration approval for its Tagrisso (osimertinib), first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC), whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations.
Competitive Landscape:
Key players operating in the global non-small cell lung cancer treatment market include Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Boehringer Ingelheim GMBH, Novartis AG, Bristol-Myers Squibb Company, and Merck & Co., Inc.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/241
Market Segmentation:
- Global Non-small Cell Lung Cancer Treatment Market, By Type:
- Adenocarcinoma
- Squamous Cell Carcinoma
- Large Cell Carcinoma
- Large Cell Neuroendocrine Tumors
- Global Non-small Cell Lung Cancer Treatment Market, By Treatment:
- Chemotherapy
- Targeted Therapy
- Bevacizumab (Avastin)
- Necitumumab (Portrazza)
- Ramucirumab (Cyramza)
- Immunotherapy
- Nivolumab (Opdivo)
- Atezolizumab (Tecentriq)
- Others
- Global Non-small Cell Lung Cancer Treatment Market, By End User:
- Hospitals
- Homecare
- Specialty Clinics
- Others
- Global Non-small Cell Lung Cancer Treatment Market, By Region:
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
- Africa
- By Region/Country
- South Africa
- Central Africa
- North Africa
- By Region/Country
- North America
Related Market Intelligence Reports:
Pediatric Clinical Trials Market, by Clinical Trial Phase (Pre-clinical, Phase I, Phase II, and Phase III), by Study Design (Treatment Studies and Observational Studies), by Medical Condition (Neuropsychiatric Conditions, Infectious Diseases, Maternal and Perinatal Conditions, Respiratory Diseases, Cardiovascular Diseases, Cancer, Digestive Diseases and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030
Cancer Immunotherapy Market, By Therapy Type (Monoclonal Antibodies, Cancer Vaccines, Immunomodulators, Immune Check Point Inhibitors, and Other Therapy Types), By Application (Prostate Cancer, Breast Cancer, Skin Cancer, Lung Cancer, and Other Applications), By End Users (Hospitals and Clinics, Cancer Research Centers, and Other End Users), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
